Diagnosis and management of pheochromocytoma

Current Problems in Surgery

Volumn 51, Issue 4, 2014, Pages 151-187

  Hodin, Richard ^a   Lubitz, Carrie ^a   Phitayakorn, Roy ^a   Stephen, Antonia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE F 18; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; CLONIDINE; DOPAMINE; DOXAZOSIN; ESMOLOL; FLUORODEOXYGLUCOSE F 18; LIDOCAINE; MAGNESIUM SULFATE; METADRENALIN; METIROSINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NORADRENALIN; NORMETADRENALIN; PENTETREOTIDE; PENTETREOTIDE IN 111; PHENOXYBENZAMINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PRAZOSIN; PROPRANOLOL; TERAZOSIN; TYRAMINE; UNINDEXED DRUG;

ABDOMINAL PAIN; ADRENAL CORTEX; ADRENAL MEDULLA; ADRENALECTOMY; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANATOMIC LANDMARK; ANESTHESIA INDUCTION; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ANXIETY; ARTICLE; BLURRED VISION; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOMYOPATHY; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE RELEASE; CATECHOLAMINE URINE LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONVERSION TO OPEN SURGERY; CUSHING SYNDROME; DEPRESSION; DIAGNOSTIC IMAGING; DIAPHORESIS; DIARRHEA; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; EXTRAPYRAMIDAL SYMPTOM; FAMILIAL DISEASE; FATIGUE; GALACTORRHEA; GENE; GENE MUTATION; GENETIC PREDISPOSITION; HAND ASSISTED LAPAROSCOPY; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INCIDENTALOMA; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; LAPAROSCOPIC SURGERY; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NF1 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PHENOTYPE; PHEOCHROMOCYTOMA; POLYDIPSIA; POLYURIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIMARY HYPERALDOSTERONISM; RECURRENCE FREE SURVIVAL; RET GENE; RETROPERITONEOSCOPIC LAPAROSCOPIC SURGERY; SDHB GENE; SDHD GENE; SENSITIVITY AND SPECIFICITY; SPLEEN INJURY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL TIME; TACHYCARDIA; THORAX PAIN; TMEM127 GENE; TRANSABDOMINAL LAPAROSCOPIC SURGERY; TUMOR LOCALIZATION; VON HIPPEL LINDAU DISEASE; WEAKNESS; WEIGHT REDUCTION;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HEART FAILURE; HUMANS; HYPERTENSION; HYPOTENSION, ORTHOSTATIC; MALE; MUTATION; PHENOTYPE; PHEOCHROMOCYTOMA; PROGNOSIS; TACHYCARDIA;

EID: 84896068154     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2013.12.001     Document Type: Article

References (259)

1. Perrier N.D., Boger M.S. Surgical anatomy. Adrenal Glands: Diagnostic Aspects and Surgical Therapy 2005, 7. Springer, New York. D. Linos, J.A. van Heerden (Eds.).
2. Udelsman R. Adrenal. Surgery: Basic Science and Clinical Evidence 2001, 897-917. Springer-Verlag, NY. J.A. Norton (Ed.).
3. Textbook of Endocrine Surgery 2005, Elsevier Saunders, Philadelphia, PA. (2nd ed). O.H. Clark, Q.Y. Duh, E. Kebebew (Eds.).
4. Current Surgical Therapy 2001, Mosby Inc, St Louis. (7th ed). J. Cameron (Ed.).
5. Beard C.M., Sheps S.G., Kurland L.T., et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983, 58:802.
6. Guerrero M.A., Schreinemakers J.M., Vriens M.R., et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg 2009, 209:727.
7. Angeli A., Osella G., Ali A., Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997, 47(4-6):279-283.
8. Kebebew E., Siperstein A.E., Clark O.H., Duh Q.Y. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg 2002, 137(8):948-953.
9. Manger W.M., Gifford R.W. Pheochromocytoma. J Clin Hypertens (Greenwich) 2002, 4:62.
10. Kebebew E., Duh Q.-Y. Pheochromocytoma. Current Surgical Therapy 2001, 624-630. Mosby Inc, St Louis. (7th ed). J. Cameron (Ed.).
11. Stein P.P., Black H.R. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution[U+05F3]s experience. Medicine (Baltimore) 1991, 70:46.
12. Bravo E.L., Gifford R.W. Pheochromocytoma. Endocrinol Metab Clin North Am 1993, 22:329.
13. Stenström G., Sjöström L., Smith U. Diabetes mellitus in phaeochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol (Copenh) 1984, 106:511.
14. Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet 2005, 366(9486):665-675.
15. Lee J.A., Zarnegar R., Shen W.T., Kebebew E., Clark O.H., Duh Q.Y. Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "subclinical" pheochromocytoma. Arch Surg 2007, 142(9):870-873.
16. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138(5):424-429.
17. Mantero F., Terzolo M., Arnaldi G., et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85(2):637-644.
18. Neumann H.P., Berger D.P., Sigmund G., et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993, 329:1531.
19. Pawlu C., Bausch B., Reisch N., Neumann H.P. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris) 2005, 66:178.
20. Neumann H.P., Vortmeyer A., Schmidt D., et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 2007, 357:1311.
21. Maher E.R., Yates J.R., Harries R., et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990, 77:1151.
22. Walther M.M., Herring J., Enquist E., et al. von Recklinghausen[U+05F3]s disease and pheochromocytomas. J Urol 1999, 162:1582.
23. Niemann S., Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26:268.
24. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69:49.
25. Jiménez C., Cote G., Arnold A., Gagel R.F. Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. J Clin Endocrinol Metab 2006, 91:2851.
26. van der Harst E., de Herder W.W., de Krijger R.R., et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 2002, 147:85-94.
27. Eisenhofer G., Walther M.M., Huynh T.T., et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001, 86:1999-2008.
28. Eisenhofer G., Lenders J.W., Siegert G., et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012, 48:1739-1749.
29. Mannelli M., Pupilli C., Lanzillotti R., et al. A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case. J Endocrinol Invest 1993, 16:817-822.
30. Pacak K., Eisenhofer G., Ahlman H., et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007, 3:92-102.
31. Lenders J.W., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. J Am Med Assoc 2002, 287:1427-1434.
32. Brain K.L., Kay J., Shine B. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clin Chem 2006, 52:2060-2064.
33. Eisenhofer G., Goldstein D.S., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003, 88:2656-2666.
34. Deutschbein T., Unger N., Jaeger A., et al. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clin Endocrinol (Oxf) 2010, 73:153-160.
35. Sawka A.M., Thabane L., Gafni A., et al. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age?. BMC Endocr Disord 2005, 5:1.
36. Willemsen J.J., Ross H.A., Lenders J.W., Sweep F.C. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clin Chem 2007, 53:268-272.
37. Darr R., Lenders J.W., Hofbauer L.C., et al. Pheochromocytoma-update on disease management. Ther Adv Endocrinol Metab 2012, 3:11-26.
38. Mullins F., O'Shea P., FitzGerald R., Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 2011, 50:105-110.
39. Pillai D., Callen S. Pilot quality assurance programme for plasma metanephrines. Ann Clin Biochem 2010, 47:137-142.
40. Lagerstedt S.A., O'Kane D.J., Singh R.J. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 2004, 50:603-611.
41. Lenders J.W., Pacak K., Huynh T., et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2010, 95:238-245.
42. Lenders Eisenhofer J.W., Mannelli G., Pacakk M. Phaeochromocytoma. Lancet 2005, 366:665-675.
43. Lee G.R., Johnston P.C., Atkinson A.B., et al. A comparison of plasma-free metanephrines with plasma catecholamines in the investigation of suspected pheochromocytoma. J Hypertens 2011, 29:2422-2428.
44. Lenders J.W., Willemsen J.J., Beissel T., Kloppenborg P.W., Thien T., Benraad T.J. Value of the plasma norepinephrine/3,4-dihydroxyphenylglycol ratio for the diagnosis of pheochromocytoma. Am J Med 1992, 92:147-152.
45. Kloos R.T., Gross M.D., Francis I.R., Korobkin M., Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995, 16:460-484.
46. Grumbach M.M., Biller B.M., Braunstein G.D., et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138:424-429.
47. Thompson G.B., Young W.F. Adrenal incidentaloma. Curr Opin Oncol 2003, 15:84-90.
48. Ilias I., Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004, 89:479-491.
49. Boland G.W., Lee M.J., Gazelle G.S., Halpern E.F., McNicholas M.M., Mueller P.R. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol 1998, 171:201-204.
50. Blake M.A., Kalra M.K., Sweeney A.T., et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006, 238:578-585.
51. Lee J.A., Duh Q.Y. Sporadic paraganglioma. World J Surg 2008, 32:683-687.
52. Motta-Ramirez G.A., Remer E.M., Herts B.R., Gill I.S., Hamrahian A.H. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. Am J Roentgenol 2005, 185:684-688.
53. Leung K., Stamm M., Raja A., Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol 2013, 200:370-378.
54. Johnson P.T., Horton K.M., Fishman E.K. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics 2009, 29:1333-1351.
55. Bessell-Browne R., O'Malley M.E. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. Am J Roentgenol 2007, 188:970-974.
56. Blake M.A., Cronin C.G., Boland G.W. Adrenal imaging. Am J Roentgenol 2010, 194:1450-1460.
57. Jacques A.E., Sahdev A., Sandrasagara M., et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 2008, 18:2885-2892.
58. Olsen W.L., Dillon W.P., Kelly W.M., Norman D., Brant-Zawadzki M., Newton T.H. MR imaging of paragangliomas. Am J Roentgenol 1987, 148:201-204.
59. Intenzo C.M., Jabbour S., Lin H.C., et al. Scintigraphic imaging of body neuroendocrine tumors. Radiographics 2007, 27:1355-1369.
60. Fujita A., Hyodoh H., Kawamura Y., Kanegae K., Furuse M., Kanazawa K. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 2000, 25:440-442.
61. van der Harst E., de Herder W.W., Bruining H.A., et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001, 86:685-693.
62. 18F-FDG) positron emission tomography. J Natl Cancer Inst 2012, 104:700-708.
63. Shulkin B.L., Thompson N.W., Shapiro B., Francis I.R., Sisson J.C. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology 1999, 212:35-41.
64. Solanki K.K., Bomanji J., Moyes J., Mather S.J., Trainer P.J., Britton K.E. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992, 13:513-521.
65. Erickson D., Kudva Y.C., Ebersold M.J., et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001, 86:5210-5216.
66. Foo S.H., Chan S.P., Ananda V., Rajasingam V. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 2010, 51:e89-e93.
67. Taieb D., Sebag F., Hubbard J.G., Mundler O., Henry J.F., Conte-Devolx B. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?. Clin Endocrinol (Oxf) 2004, 61:102-108.
68. Timmers H.J., Kozupa A., Chen C.C., et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007, 25:2262-2269.
69. Vanderveen K.A., Thompson S.M., Callstrom M.R., et al. Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 2009, 146:1158-1166.
70. Pomares F.J., Canas R., Rodriguez J.M., Hernandez A.M., Parrilla P., Tebar F.J. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 1998, 48:195-200.
71. Amar L., Baudin E., Burnichon N., et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007, 92:3822-3828.
72. Neumann H.P., Pawlu C., Peczkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. J Am Med Assoc 2004, 292:943-951.
73. Gimenez-Roqueplo A.P., Caumont-Prim A., Houzard C., et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013, 98:E162-E173.
74. Fonte J.S., Robles J.F., Chen C.C., et al. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer 2012, 19:83-93.
75. Pacak K., Eisenhofer G., Carrasquillo J.A., Chen C.C., Whatley M., Goldstein D.S. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. Ann N Y Acad Sci 2002, 970:170-176.
76. Bovio S., Cataldi A., Reimondo G., et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006, 29:298-302.
77. Song J.H., Chaudhry F.S., Mayo-Smith W.W. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. Am J Roentgenol 2008, 190:1163-1168.
78. Freel E.M., Stanson A.W., Thompson G.B., et al. Adrenal venous sampling for catecholamines: a normal value study. J Clin Endocrinol Metab 2010, 95:1328-1332.
79. Welbourn R.B. Early surgical history of phaeochromocytoma. Br J Surg 1987, 74:594-596.
80. Favia G., Lumachi F., Polistina F., D'Amico D.F. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg 1998, 22:689-693. [discussion 694].
81. Orchard T., Grant C.S., van Heerden J.A., Weaver A. Pheochromocytoma--continuing evolution of surgical therapy. Surgery 1993, 114:1153-1158. [discussion 1158-1159].
82. Ulchaker J.C., Goldfarb D.A., Bravo E.L., Novick A.C. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 1999, 161:764-767.
83. Obara T., Kanbe M., Okamoto T., et al. Surgical strategy for pheochromocytoma: emphasis on the pledge of flank extraperitoneal approach in selected patients. Surgery 1995, 118:1083-1089.
84. Plouin P.F., Duclos J.M., Soppelsa F., et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001, 86:1480-1486.
85. Liao W.B., Liu C.F., Chiang C.W., et al. Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med 2000, 18:622-625.
86. Boutros A.R., Bravo E.L., Zanettin G., Straffon R.A. Perioperative management of 63 patients with pheochromocytoma. Cleve Clin J Med 1990, 57:613-617.
87. Bravo E.L. Pheochromocytoma. Curr Ther Endocrinol Metab 1997, 6:195-197.
88. Kinney M.A., Warner M.E., vanHeerden J.A., et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg 2000, 91:1118-1123.
89. Witteles R.M., Kaplan E.L., Roizen M.F. Safe and cost-effective preoperative preparation of patients with pheochromocytoma. Anesth Analg 2000, 91:302-304.
90. Bogolioubov A., Keefe D.L., Groeger J.S. Circulatory shock. Crit Care Clin 2001, 17:697-719.
91. Organization PaPRS: Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium on Pheochromocytoma-ISP2005; 2005.
92. Prys-Roberts C., Farndon J.R. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 2002, 26:1037-1042.
93. Zhu Y., He H.C., Su T.W., et al. Selective alpha1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma. Endocrine 2010, 38:254-259.
94. Weingarten T.N., Cata J.P., O'Hara J.F., et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology 2010, 76:508.e506-508.e511.
95. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007, 92:4069-4079.
96. Lebuffe G., Dosseh E.D., Tek G., et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005, 60:439-444.
97. Nagatsu T., Mizutani K., Sudo Y., Nagatsu I. Tyrosine hydroxylase in human adrenal glands and human pheochromocytoma. Clin Chim Acta 1972, 39:417-424.
98. Steinsapir J., Carr A.A., Prisant L.M., Bransome E.D. Metyrosine and pheochromocytoma. Arch Intern Med 1997, 157:901-906.
99. Graham G.W., Unger B.P., Coursin D.B. Perioperative management of selected endocrine disorders. Int Anesthesiol Clin 2000, 38:31-67.
100. Engelman K., Sjoerdsma A. A new test for pheochromocytoma. pressor responsiveness to tyramine. J Am Med Assoc 1964, 189:81-86.
101. Naila A., Flint S., Fletcher G., et al. Control of biogenic amines in food--existing and emerging approaches. J Food Sci 2010, 75:R139-R150.
102. Tauzin-Fin P., Sesay M., Gosse P., Ballanger P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 2004, 92:512-517.
103. Kinney M.A., Narr B.J., Warner M.A. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002, 16:359-369.
104. Whalley D.G., Berrigan M.J. Anesthesia for radical prostatectomy, cystectomy, nephrectomy, pheochromocytoma, and laparoscopic procedures. Anesthesiol Clin North America 2000, 18:899-917. (x).
105. Bryskin R., Weldon B.C. Dexmedetomidine and magnesium sulfate in the perioperative management of a child undergoing laparoscopic resection of bilateral pheochromocytomas. J Clin Anesth 2010, 22:126-129.
106. Connery L.E., Coursin D.B. Assessment and therapy of selected endocrine disorders. Anesthesiol Clin North America 2004, 22:93-123.
107. Cooper Z.A., Mihm F.G. Blood pressure control with fenoldopam during excision of a pheochromocytoma. Anesthesiology 1999, 91:558-560.
108. Minami T., Adachi T., Fukuda K. An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Anesth Analg 2002, 95:1243-1244. [table of contents].
109. McMillian W.D., Trombley B.J., Charash W.E., Christian R.C. Phentolamine continuous infusion in a patient with pheochromocytoma. Am J Health Syst Pharm 2011, 68:130-134.
110. Kobal S.L., Paran E., Jamali A., et al. Pheochromocytoma: cyclic attacks of hypertension alternating with hypotension. Nat Clin Pract Cardiovasc Med 2008, 5:53-57.
111. Engelbrecht E.R., Hugill J.T., Graves H.B. Anaesthetic management of pheochromocytoma. Can Anaesth Soc J 1966, 13:598-606.
112. Grasselli G., Foti G., Patroniti N., et al. Extracorporeal cardiopulmonary support for cardiogenic shock caused by pheochromocytoma: a case report and literature review. Anesthesiology 2008, 108:959-962.
113. Chambers S., Espiner E.A., Donald R.A., Nicholls M.G. Hypoglycaemia following removal of phaeochromocytoma: case report and review of the literature. Postgrad Med J 1982, 58:503-506.
114. Reynolds C., Wilkins G.E., Schmidt N., et al. Hyperinsulinism after removal of a pheochromocytoma. Can Med Assoc J 1983, 129:349-353.
115. Akiba M., Kodama T., Ito Y., et al. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg 1990, 14:317-324.
116. Martin R., St-Pierre B., Moliner O.R. Phaeochromocytoma and postoperative hypoglycaemia. Can Anaesth Soc J 1979, 26:260-262.
117. Jude E.B., Sridhar C.B. Prolonged hypoglycaemia following surgical removal of phaeochromocytoma. Postgrad Med J 2000, 76:39-40.
118. Hansen P., Bax T., Swanstrom L. Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Endoscopy 1997, 29:309.
119. Wells S.A., Merke D.P., Cutler G.B., et al. Therapeutic controversy: the role of laparoscopic surgery in adrenal disease. J Clin Endocrinol Metab 1998, 83:3041.
120. Brunt L.M. Minimal access adrenal surgery. Surg Endosc 2006, 20:351.
121. Gumbs A.A., Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab 2006, 20:483.
122. Gagner M., Pomp A., Heniford B.T., et al. Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures. Ann Surg 1997, 226:238.
123. Lee J., El-Tamer M., Schifftner T., et al. Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program. J Am Coll Surg 2008, 206:953.
124. Miller B.S., Ammori J.B., Gauger P.G., et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010, 34:1380.
125. Schteingart D.E., Doherty G.M., Gauger P.G., et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005, 12:667.
126. Gonzalez R.J., Shapiro S., Sarlis N., et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005, 138:1078.
127. Porpiglia F., Fiori C., Daffara F., et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010, 57:873.
128. Brix D., Allolio B., Fenske W., et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010, 58:609.
129. McCauley L.R., Nguyen M.M. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol 2008, 18:134.
130. Adler J.T., Mack E., Chen H. Equal oncologic results for laparoscopic and open resection of adrenal metastases. J Surg Res 2007, 140:159.
131. Suzuki H. Laparoscopic adrenalectomy for adrenal carcinoma and metastases. Curr Opin Urol 2006, 16:47.
132. Lombardi C.P., Raffaelli M., De Crea C., Bellantone R. Role of laparoscopy in the management of adrenal malignancies. J Surg Oncol 2006, 94:128.
133. Porpiglia F., Miller B.S., Manfredi M., et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011, 2:372.
134. Bennett I.C., Ray M. Hand-assisted laparoscopic adrenalectomy: an alternative minimal invasive surgical technique for the adrenal gland. ANZ J Surg 2002, 72(11):801-805.
135. Callender G.G., Kennamer D.L., Grubbs E.G., et al. Posterior retroperitoneoscopic adrenalectomy. Adv Surg 2009, 43:147.
136. Walz M.K., Alesina P.F., Wenger F.A., et al. Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery 2006, 140:943.
137. Perrier N.D., Kennamer D.L., Bao R., et al. Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg 2008, 248:666.
138. Dickson P.V., Jimenez C., Chisholm G.B., et al. Posterior retroperitoneoscopic adrenalectomy: a contemporary American experience. J Am Coll Surg 2011, 212:659.
139. Constantinides V.A., Christakis I., Touska P., Palazzo F.F. Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy. Br J Surg 2012, 99:1639.
140. Shen W.T., Kebebew E., Clark O.H., Duh Q.Y. Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003. World J Surg 2004, 28:1176.
141. Shen Z.J., Chen S.W., Wang S., et al. Predictive factors for open conversion of laparoscopic adrenalectomy: a 13-year review of 456 cases. J Endourol 2007, 21:1333-1339.
142. Pathology and Genetics of Tumours of the Endocrine Organs. WHO Classification of Tumours 2004, IARC press, Lyon, France. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (Eds.).
143. Chen H., Sippel R.S., O'Dorisio M.S., et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010, 39:775.
144. Ayala-Ramirez M., Feng L., Johnson M.M., et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011, 96:717.
145. Eisenhofer G., Bornstein S.R., Brouwers F.M., et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004, 11:423.
146. Sisson J.C., Shulkin B.L., Esfandiari N.H. Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci 2006, 1073:505.
147. Moskovic D.J., Smolarz J.R., Stanley D., et al. Malignant head and neck paragangliomas: is there an optimal treatment strategy?. Head Neck Oncol 2010, 2:23.
148. Pacak K., Ilias I., Adams K.T., Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005, 257:60.
149. Schlumberger M., Gicquel C., Lumbroso J., et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992, 15:631.
150. Andersen K.F., Altaf R., Krarup-Hansen A., et al. Malignant pheochromocytomas and paragangliomas-the importance of a multidisciplinary approach. Cancer Treat Rev 2011, 37:111.
151. Mukherji S.K., Kasper M.E., Tart R.P., Mancuso A.A. Irradiated paragangliomas of the head and neck: CT and MR appearance. Am J Neuroradiol 1994, 15:357.
152. Argiris A., Mellott A., Spies S. PET scan assessment of chemotherapy response in metastatic paraganglioma. Am J Clin Oncol 2003, 26:563.
153. 131I-MIBG. Horm Metab Res 2012, 44:405.
154. Teno S., Tanabe A., Nomura K., Demura H. Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma. Endocr J 1996, 43:511.
155. Safford S.D., Coleman R.E., Gockerman J.P., et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003, 134:956.
156. Shapiro B., Sisson J.C., Wieland D.M., et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991, 35:269.
157. Shilkrut M., Bar-Deroma R., Bar-Sela G., et al. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol 2010, 33:79.
158. 131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009, 27:4162.
159. McBride J.F., Atwell T.D., Charboneau W.J., et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011, 22:1263.
160. Mamlouk M.D., vanSonnenberg E., Stringfellow G., et al. Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers. J Vasc Interv Radiol 2009, 20:670.
161. Wood B.J., Abraham J., Hvizda J.L., et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003, 97:554.
162. Pacak K., Fojo T., Goldstein D.S., et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001, 93:648.
163. Cozzi P.J., Englund R., Morris D.L. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995, 76:501.
164. Hidaka S., Hiraoka A., Ochi H., et al. Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE). Intern Med 2010, 49:645.
165. Watanabe D., Tanabe A., Naruse M., et al. Transcatheter arterial embolization for the treatment of liver metastases in a patient with malignant pheochromocytoma. Endocr J 2006, 53:59.
166. Takahashi K., Ashizawa N., Minami T., et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 1999, 38:349.
167. Mundschenk J., Unger N., Schulz S., et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003, 88:5150.
168. Gulenchyn K.Y., Yao X., Asa S.L., et al. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol) 2012, 24:294.
169. Cecchin D., Schiavi F., Fanti S., et al. Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. J Clin Oncol 2011, 29:e171.
170. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010, 116:1084.
171. Koriyama N., Kakei M., Yaekura K., et al. Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies. Horm Res 2000, 53:46.
172. Lamarre-Cliche M., Gimenez-Roqueplo A.P., Billaud E., et al. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002, 57:629.
173. Invitti C., De Martin I., Bolla G.B., et al. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993, 40:156.
174. Plouin P.F., Bertherat J., Chatellier G., et al. Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clin Endocrinol (Oxf) 1995, 42:289.
175. Ayala-Ramirez M., Feng L., Habra M.A., et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012, 118:2804.
176. Nomura K., Kimura H., Shimizu S., et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 2009, 94:2850.
177. Patel S.R., Winchester D.J., Benjamin R.S. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 1995, 76:1476.
178. Huang H., Abraham J., Hung E., et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008, 113:2020.
179. Averbuch S.D., Steakley C.S., Young R.C., et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988, 109:267.
180. Bravo E.L., Kalmadi S.R., Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res 2009, 41:703.
181. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24:401.
182. Mora J., Cruz O., Parareda A., et al. Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatr Blood Cancer 2009, 53:663.
183. Kruijtzer C.M., Beijnen J.H., Swart M., Schellens J.H. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother Pharmacol 2000, 45:428.
184. Joshua A.M., Ezzat S., Asa S.L., et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009, 94:5.
185. Jimenez C., Cabanillas M.E., Santarpia L., et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009, 94:386.
186. Hahn N.M., Reckova M., Cheng L., et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009, 27:460.
187. Park K.S., Lee J.L., Ahn H., et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 2009, 39:327.
188. Ayala-Ramirez M., Chougnet C.N., Habra M.A., et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 2012, 97:4040.
189. Tumours of the Paraganglionic System: Introduction 2005, IARC press, Lyon, France. L. Barnes, J.W. Evenson, P. Reichart, D. Sidreansky (Eds.).
190. Gimenez-Roqueplo A.P., Dahia P.L., Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012, 44:328-333.
191. Fishbein L., Merrill S., Fraker D.L., Cohen D.L., Nathanson K.L. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 2013, 20:1444-1450.
192. Chen H., Sippel R.S., O'Dorisio M.S., Vinik A.I., Lloyd R.V., Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010, 39:775-783.
193. Welander J., Soderkvist P., Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011, 18:R253-R276.
194. Armstrong M.J., Chiosea S.I., Carty S.E., Hodak S.P., Yip L. Thyroid paragangliomas are locally aggressive. Thyroid 2012, 22:88-93.
195. Matsumoto M., Abe K., Baba H., et al. Paraganglioma of the cauda equina: a report of two cases with unusual histopathological features. Clin Neuropathol 2012, 31:39-43.
196. Deng J.H., Li H.Z., Zhang Y.S., Liu G.H. Functional paragangliomas of the urinary bladder: a report of 9 cases. Chin J Cancer 2010, 29:729-734.
197. van Duinen N., Steenvoorden D., Kema I.P., et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab 2010, 95:209-214.
198. Sawka A.M., Jaeschke R., Singh R.J., Young W.F. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003, 88:553-558.
199. Eisenhofer G., Goldstein D.S., Sullivan P., et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005, 90:2068-2075.
200. Bustillo A., Telischi F., Weed D., et al. Octreotide scintigraphy in the head and neck. Laryngoscope 2004, 114:434-440.
201. 18F-FDG. Cancer 2008, 112:2447-2455.
202. 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med 2009, 50:397-400.
203. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003, 30:689-694.
204. 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging 2012, 39:1144-1153.
205. Fiebrich H.B., Brouwers A.H., Kerstens M.N., et al. 6-[F-18]fluoro-l-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009, 94:3922-3930.
206. Lodish M.B., Adams K.T., Huynh T.T., et al. Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. Endocr Relat Cancer 2010, 17:581-588.
207. Klein R.D., Jin L., Rumilla K., Young W.F., Lloyd R.V. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol 2008, 17:94-100.
208. Laird A.M., Gauger P.G., Doherty G.M., Miller B.S. Paraganglioma: not just an extra-adrenal pheochromocytoma. Langenbecks Arch Surg 2012, 397:247-253.
209. Eisenhofer G., Tischler A.S., de Krijger R.R. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol 2012, 23:4-14.
210. Pinato D.J., Ramachandran R., Toussi S.T., et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 2013, 108:429-437.
211. Clarke M.R., Weyant R.J., Watson C.G., Carty S.E. Prognostic markers in pheochromocytoma. Hum Pathol 1998, 29:522-526.
212. Kimura N., Watanabe T., Noshiro T., Shizawa S., Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 2005, 16:23-32.
213. Strong V.E., Kennedy T., Al-Ahmadie H., et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008, 143:759-768.
214. Thompson L.D. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002, 26:551-566.
215. Young A.L., Baysal B.E., Deb A., Young W.F. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 2002, 87:4101-4105.
216. Amar L., Servais A., Gimenez-Roqueplo A.P., Zinzindohoue F., Chatellier G., Plouin P.F. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005, 90:2110-2116.
217. Bosca Robledo A., Ponce Marco J.L., Belda Ibanez T., Meseguer Anastasio M.F., Gomez Gavara C. Pheochromocytomatosis: a risk after pheochromocytoma surgery. Am Surg 2010, 76:E122-E124.
218. Janetschek G., Finkenstedt G., Gasser R., et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998, 160:330-334.
219. Mitchell J., Siperstein A., Milas M., Berber E. Laparoscopic resection of abdominal paragangliomas. Surg Laparosc Endosc Percutan Tech 2011, 21:e48-e53.
220. Adjalle R., Plouin P.F., Pacak K., Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009, 41:687-696.
221. Cheng L., Leibovich B.C., Cheville J.C., et al. Paraganglioma of the urinary bladder: can biologic potential be predicted?. Cancer 2000, 88:844-852.
222. van Heerden J.A., Roland C.F., Carney J.A., Sheps S.G., Grant C.S. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg 1990, 14:325-329.
223. Burnichon N., Briere J.J., Libe R., et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010, 19:3011-3020.
224. Schlisio S., Kenchappa R.S., Vredeveld L.C., et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008, 22:884-893.
225. Ladroue C., Carcenac R., Leporrier M., et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008, 359:2685-2692.
226. Qin Y., Yao L., King E.E., et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010, 42:229-233.
227. Comino-Mendez I., Gracia-Aznarez F.J., Schiavi F., et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011, 43:663-667.
228. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002, 346:1459-1466.
229. Mannelli M., Castellano M., Schiavi F., et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 2009, 94:1541-1547.
230. Woodward E.R., Maher E.R. von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 2006, 13:415-425.
231. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
232. Shuin T., Yamasaki I., Tamura K., Okuda H., Furihata M., Ashida S. von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 2006, 36:337-343.
233. Woodward E.R., Eng C., McMahon R., et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 1997, 6:1051-1056.
234. Nielsen S.M., Rubinstein W.S., Thull D.L., et al. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A 2011, 155A:168-173.
235. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
236. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26:268-270.
237. Astuti D., Hart-Holden N., Latif F., et al. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) 2003, 59:728-733.
238. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006, 91:827-836.
239. Bayley J.P., Kunst H.P., Cascon A., et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 2010, 11:366-372.
240. Kunst H.P., Rutten M.H., de Monnink J.P., et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res 2011, 17:247-254.
241. Astuti D., Douglas F., Lennard T.W., et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001, 357:1181-1182.
242. Schiavi F., Boedeker C.C., Bausch B., et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. J Am Med Assoc 2005, 294:2057-2063.
243. Ricketts C.J., Forman J.R., Rattenberry E., et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010, 31:41-51.
244. Korpershoek E., Favier J., Gaal J., et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011, 96:E1472-E1476.
245. Young W.F., Abboud A.L. Editorial: paraganglioma-all in the family. J Clin Endocrinol Metab 2006, 91:790-792.
246. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856.
247. Wells S.A., Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009, 15:7119-7123.
248. Walther M.M., Herring J., Enquist E., Keiser H.R., Linehan W.M. von Recklinghausen[U+05F3]s disease and pheochromocytomas. J Urol 1999, 162:1582-1586.
249. Stratakis C.A., Carney J.A. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009, 266:43-52.
250. Janeway K.A., Kim S.Y., Lodish M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011, 108:314-318.
251. Matyakhina L., Bei T.A., McWhinney S.R., et al. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007, 92:2938-2943.
252. Pasini B., McWhinney S.R., Bei T., et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16:79-88.
253. Burnichon N., Cascon A., Schiavi F., et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012, 18:2828-2837.
254. Eisenhofer G., Huynh T.T., Pacak K., et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004, 11:897-911.
255. Hensen E.F., Goeman J.J., Oosting J., et al. Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC Med Genomics 2009, 2:25.
256. Favier J., Gimenez-Roqueplo A.P. Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab 2010, 24:957-968.
257. Pollard P.J., El-Bahrawy M., Poulsom R., et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 2006, 91:4593-4598.
258. Gill A.J., Benn D.E., Chou A., et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 2010, 41:805-814.
259. van Nederveen F.H., Gaal J., Favier J., et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009, 10:764-771.